Categorisation of Nominated Substances: Because the evaluation process is extensive and ongoing, the FDA categorises "nominated" substances that have not yet reached a final decision
Engineered with structural modifications that improve molecular stability compared to endogenous GLP-1, Semaglutide has become one of the most widely studied compounds within metabolic and endocrine research
Both the new study and my commentary are now available open access on the JACC website, as of this morning.) Since last year, weve known that Wegovy recipients in the SELECT trial had lower cardiovascular disease and all-cause mortality than placebo recipients (the latter finding especially got my attention)
Selecting an appropriate weight loss injection requires careful consideration of individual tolerance, medical history, and treatment goals
Understanding the Post-GLP-1 Challenge The STEP 1 trial extension found that one year after withdrawal of semaglutide and lifestyle intervention, participants regained two-thirds of their prior weight loss